US
US Microbiome Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Product, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $397.3 Mn.
Canada at 30% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$3.29 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $310.1 Mn | — | — |
| 2025 (base) | $397.3 Mn | +$87.1 Mn | — |
| 2026 (forecast) | $508.9 Mn | +$111.6 Mn | +28.1% |
| 2027 (forecast) | $651.9 Mn | +$143.0 Mn | +64.1% |
| 2028 (forecast) | $835.1 Mn | +$183.2 Mn | +110.2% |
| 2029 (forecast) | $1.07 Bn | +$234.7 Mn | +169.3% |
| 2030 (forecast) | $1.37 Bn | +$300.6 Mn | +244.9% |
| 2031 (forecast) | $1.76 Bn | +$385.1 Mn | +341.9% |
| 2032 (forecast) | $2.25 Bn | +$493.3 Mn | +466% |
| 2033 (forecast) | $2.88 Bn | +$631.9 Mn | +625.1% |
| 2034 (forecast) | $3.69 Bn | +$809.5 Mn | +828.8% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$397.3 Mn
Canada
$92.6 Mn
China
$78.1 Mn
Japan
$58.2 Mn
Germany
$34.6 Mn
Italy
$27.1 Mn
France
$26.1 Mn
UK
$24.2 Mn
Ecuador
$22.8 Mn
Brazil
$22.2 Mn
Spain
$21.0 Mn
Saudi Arabia
$18.2 Mn
India
$18.1 Mn
Mexico
$13.1 Mn
New Zealand
$11.5 Mn
Australia
$11.0 Mn
Russia
$9.4 Mn
South Africa
$6.3 Mn
UAE
$5.3 Mn
Egypt
$3.1 Mn
Philippines
$1.9 Mn
Hong Kong
$1.5 Mn
Malaysia
$1.4 Mn
Singapore
$1.4 Mn
Thailand
$1.2 Mn
Kenya
$0.9 Mn
Microbiome therapeutics use live bacteria or their products as medicines, for infections, bowel disease and other conditions.
Key segments of the microbiome Therapeutics market include product (Fecal Microbiota Products, Live Biotherapeutics and Microbiome Modulators) and indication (C. difficile, IBD and Oncology).
Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the microbiome Therapeutics market.
Microbiome-based treatments, earlier testing and digital gut-health programmes give the microbiome Therapeutics market room to grow.
Late diagnosis, stigma, limited specialist access and high prices of new medicines hold back the microbiome Therapeutics market.
The microbiome Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for microbiome Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
What doctors and scientists are doing in Microbiome Therapeutics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
OTC & Nutraceuticals · US
Medical Devices · US
Healthcare Services · US
Healthcare Services · US
Medical Devices · US
Healthcare Services · US